Result of Annual General Meeting

RNS Number : 9657H

Allergy Therapeutics PLC

08 December 2020

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Result of Annual General Meeting

8 December 2020 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that, with the exception of resolution 10, which failed to carry, all other resolutions proposed at the 2020 Annual General Meeting ("AGM") were duly passed by shareholders. Voting was conducted by way of a poll.  

Resolutions 1 to 9 (inclusive) were proposed as ordinary resolutions and resolution 10 was proposed as a special resolution. The results of the poll are outlined in the table below.

The Board acknowledges the failure to pass resolution 10 and is disappointed in this outcome. The Board considers the flexibility afforded by these authorities to be in the best interests of the Company and shareholders and notes that this resolution has received support at previous AGMs. However, the Board remains committed to continuing an open and transparent dialogue and will, accordingly, seek to continue to engage with shareholders regarding their views in this area.

Resolution	For:	%age	Against:	%age	Total Votes Cast	% of ISC	Withheld
1. to receive a copy of the Annual Report for the year ended 30 June 2020	556,845,254	100	0	0	556,845,254	87.03	26,857
2. To approve the Directors' Remuneration Report	554,801,389	99.64	1,990,053	0.36	556,791,442	87.02	80,669
3. To re-appoint Manuel Llobet as a Director	556,845,611	100	0	0	556,845,611	87.03	26,500
4. To re-appoint Nicolas Wykeman as a Director	556,821,111	99.99	25,000	0.01	556,846,111	87.03	26,000
5. To re-appoint Steve Smith as a Director	554,199,787	99.53	2,636,967	0.47	556,836,754	87.02	35,357
6. To re-appoint Peter Jensen as a Director	554,200,287	99.6	2,211,900	0.4	556,412,187	86.96	459,924
7. To re-appoint Grant Thornton LLP as auditors of the Company	554,851,201	99.64	2,007,553	0.36	556,858,754	87.03	13,357
8. To authorise the Directors to determine the Auditors remuneration	556,787,942	99.99	25,000	0.01	556,812,942	87.02	59,169
9. To authorise the Directors to allot the unissued share capital up to a specified amount (s.551)	281,855,864	50.8	272,997,694	49.2	554,853,558	86.71	2,018,553
10. Special Resolution: To disapply pre-emption provisions of s.561(1) of the Companies Act 2006 up to a specified amount	281,828,810	50.61	274,980,390	49.39	556,809,200	87.02	62,911

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Deardon, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia Manser

[e-mail]

Stern Investor Relations, Inc.

[phone]

Christina Tartaglia

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

 

END

 

 

RAGKKFBQQBDDDBK